Adaptive Biotechnologies (ADPT) Liabilities and Shareholders Equity (2018 - 2025)
Adaptive Biotechnologies (ADPT) has disclosed Liabilities and Shareholders Equity for 8 consecutive years, with $512.7 million as the latest value for Q4 2025.
- Quarterly Liabilities and Shareholders Equity fell 4.94% to $512.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.0 billion through Dec 2025, down 12.69% year-over-year, with the annual reading at $512.7 million for FY2025, 4.94% down from the prior year.
- Liabilities and Shareholders Equity hit $512.7 million in Q4 2025 for Adaptive Biotechnologies, up from $490.6 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.1 billion in Q1 2021 to a low of $490.6 million in Q3 2025.
- Historically, Liabilities and Shareholders Equity has averaged $733.8 million across 5 years, with a median of $741.1 million in 2023.
- Biggest five-year swings in Liabilities and Shareholders Equity: increased 22.54% in 2021 and later fell 23.5% in 2024.
- Year by year, Liabilities and Shareholders Equity stood at $923.3 million in 2021, then dropped by 7.23% to $856.6 million in 2022, then dropped by 22.82% to $661.1 million in 2023, then decreased by 18.42% to $539.4 million in 2024, then fell by 4.94% to $512.7 million in 2025.
- Business Quant data shows Liabilities and Shareholders Equity for ADPT at $512.7 million in Q4 2025, $490.6 million in Q3 2025, and $496.6 million in Q2 2025.